The bioMérieux share price rose on Tuesday on the Paris Bourse, buoyed by Deutsche Bank's initiation of buy coverage.

Shortly before 11:00 am, the diagnostics specialist's shares gained 1%, while the SBF 120 index advanced by 0.2%.

The analyst initiated coverage of the stock with a price target of 121 euros, praising the group's flattering track record in terms of profitable growth.

Deutsche expects average annual sales growth of 7% over the 2023-2028 period, and Ebit growth of 11%, outperforming both its market and competitors.

This dynamism, he explains, should be underpinned by the extension of the offering into new specialties, by an already solid product portfolio, and by the quality of the management team.

In view of these catalysts and its attractive positioning in niche segments, the intermediary believes that its valuation is attractive today, based on a PER 2025 of 22x.

Copyright (c) 2024 All rights reserved.